EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> French biotech Seekyo raised an €800,000 ($889,000) seed round. Seekyo will use the money to advance its lead chemotherapy ahead of a planned fundraising round to support clinical development. Release

> Otsuka Pharmaceutical entered into a drug discovery pact with PhoreMost. The partners plan to identify novel targets amenable to treatment with gene therapies. Statement 

> HepaRegeniX raised an €11 million ($12 million) series B round. The money will support the start of clinical tests of a MKK4 inhibitor developed for use in acute and chronic liver diseases. Release 

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> The FDA cleared Abivax to start a phase 2b trial of ABX464 in patients with moderate to severe ulcerative colitis. Enrollment is due to start in the second quarter. Statement 

> Autolus Therapeutics priced a public offering to raise around $80 million. Release 

Suggested Articles

An inhaled drug developed by Aridis eradicated the novel coronavirus from infected hamsters at a much lower dose than other antibody treatments.

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.